Chandan H1 revenue rises 41% as operating margin expands
Key highlights
- Chandan's H1 FY27 standalone revenue rose 41.16% to Rs 106.61 crore.
- H1 FY27 EBITDA increased 66.52% to Rs 40.31 crore and margin rose 576 basis points to 36.95%.
- Reported H1 FY27 PAT of Rs 25.37 crore included a Rs 10.23 crore post-tax pharmacy-sale gain.
- Chandan had 685 franchise centres on 30 September 2026 and management targets 1,000 by FY27-end.
powered by IRIS

Chandan Healthcare Limited reported 41.16% revenue growth to Rs 106.61 crore in the first half of FY27 (H1 FY27), while earnings before interest, tax, depreciation and amortisation (EBITDA) margin increased 576 basis points to 36.95%; reported profit included a Rs 10.23 crore post-tax gain from the pharmacy stake sale.
Know Chandan Healthcare inside out
Results, valuation, peers and who's buying, in one view.
How did Chandan's H1 FY27 revenue and operating profit change?
Chandan increased H1 FY27 revenue to Rs 106.61 crore from Rs 75.53 crore in H1 FY26, while EBITDA rose 66.52% to Rs 40.31 crore from Rs 24.21 crore. Total income, including other income, increased 40.56% to Rs 109.12 crore from Rs 77.63 crore. Reported profit after tax (PAT) rose to Rs 25.37 crore from Rs 7.11 crore, although it included an exceptional pharmacy-sale gain.
The H1 FY27 result was prepared on a standalone basis, following the deconsolidation of the pharmacy business. Other income increased to Rs 2.51 crore from Rs 2.11 crore, while operating income reached Rs 106.61 crore. The presentation states that prior-year comparatives are also the standalone financials of Chandan.
Second-quarter revenue was Rs 57.94 crore, up 45.04% from Rs 39.95 crore in Q2 FY26 and 19.06% from Rs 48.67 crore in Q1 FY27. Q2 FY27 therefore accounted for more than half of H1 FY27 revenue of Rs 106.61 crore. Total income in Q2 FY27 was Rs 59.36 crore, compared with Rs 49.76 crore in Q1 FY27.
Why did Chandan's EBITDA margin expand by 576 basis points?
Chandan's H1 FY27 EBITDA margin rose to 36.95% from 31.18% in H1 FY26 because EBITDA growth of 66.52% exceeded total-income growth of 40.56%. The 576-basis-point increase equals 5.76 percentage points. The presentation defines EBITDA as total income less total expenditure.
Total expenditure increased to Rs 68.80 crore in H1 FY27 from Rs 53.42 crore in H1 FY26, while total income reached Rs 109.12 crore from Rs 77.63 crore. Employee benefit expenses increased to Rs 27.03 crore from Rs 22.07 crore, raw-material expenses rose to Rs 16.32 crore from Rs 14.49 crore, and other expenses reached Rs 25.45 crore from Rs 16.86 crore.
The quarterly figures show a further margin increase within H1 FY27. Q2 FY27 EBITDA was Rs 22.12 crore, 21.57% higher than Rs 18.19 crore in Q1 FY27, and the EBITDA margin increased 69 basis points from 36.57% to 37.26%. Against Q2 FY26, EBITDA rose 54.79% from Rs 14.29 crore and margin increased 241 basis points from 34.85%.
How much of Chandan's H1 FY27 profit came from the pharmacy sale?
Chandan's reported H1 FY27 PAT of Rs 25.37 crore included a Rs 10.23 crore net-of-tax exceptional gain from selling its investment in Chandan Pharmacy Limited. The gain was Rs 12.03 crore before tax, and Rs 1.80 crore of tax on that gain was included in the tax charge. The presentation says the gain was not part of regular operations.
Adjusted PAT, excluding the net gain, was Rs 15.14 crore in H1 FY27 compared with Rs 7.11 crore in H1 FY26, an increase of 112.91%. Adjusted PAT margin rose 471 basis points to 13.87% from 9.16%. Reported PAT margin was 23.25%, up 1,409 basis points, because it retained the exceptional item.
The difference was also material in Q2 FY27. Reported PAT was Rs 18.61 crore, compared with adjusted PAT of Rs 8.38 crore, after the Rs 10.23 crore net gain. Q2 reported PAT increased 224.19% from Rs 5.74 crore in Q2 FY26, while adjusted PAT increased 46.04%; profit before tax before the exceptional item rose 63.88% to Rs 12.91 crore.
Got a follow-up? Ask IRIS
What is Chandan's plan after the pharmacy divestment?
Chandan plans to focus capital and management attention on diagnostics after divesting its entire 53.56% stake in the pharmacy business, effective 1 September 2026. Management said the pharmacy operation was low margin and that more than 70% of its revenue came from business-to-business (B2B) supply. Management also said the sale proceeds would be directed towards new diagnostic centres.
Franchising is the principal stated expansion route. Franchise centres increased from 235 on 31 March 2026 to 264 on 30 June 2026 and 685 on 30 September 2026. Management has set a target of 1,000 centres by the end of FY27 and 3,000 over the following two years; around 80% of the network was in Uttar Pradesh at the time of the presentation.
Under the franchise model, partners bear local infrastructure and operating costs, while Chandan provides diagnostics capability, quality protocols, branding and support. Samples collected at franchise points are routed to a Chandan laboratory or diagnostic centre. Management said it would also add owned centres, scale work with Jeena Sikho hospitals and clinics, grow business-to-government activity and improve network utilisation during the rest of FY27.
Chandan also agreed on 25 September 2026 to acquire two Ansh Diagnostics & Health Care units in Ghaziabad, Uttar Pradesh. The units provide pathology and radiology services, including computed tomography (CT) and magnetic resonance imaging (MRI). The presentation describes the transaction as adding established operating facilities and supporting its presence in the Delhi National Capital Region.
Conclusion
Chandan's H1 FY27 performance combined 41.16% revenue growth to Rs 106.61 crore with EBITDA growth of 66.52% to Rs 40.31 crore, producing a 576-basis-point margin increase. The reported PAT increase to Rs 25.37 crore should be separated from the underlying result, as adjusted PAT was Rs 15.14 crore after excluding the Rs 10.23 crore post-tax pharmacy-sale gain.
The next disclosed measures are progress towards management's target of 1,000 franchise centres by FY27-end, additions of owned diagnostic centres and deployment of pharmacy-sale proceeds into diagnostics. The planned expansion in Jeena Sikho work, business-to-government activity and newer geographies, as well as integration of the two Ghaziabad units agreed on 25 September 2026, are further items to watch.


